NCT03936465: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

NCT03936465
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BET, BRD, MYC, MYCN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 21 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients with 1) amplification or translocation MYCN or MYC, or 2) translocation of BRD3 or BRD4 will be assigned to Cohort B; All others will be assigned to Cohort A
Exclusions: 
https://ClinicalTrials.gov/show/NCT03936465

Comments are closed.

Up ↑